Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 768-778

  Frumovitz, Michael ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Gynecologic cancer; Vascular endothelial growth factor (VEGF)

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOZYME; ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MONOCLONAL ANTIBODY 2 C3; PACLITAXEL; SORAFENIB; SUNITINIB; TOPOTECAN; UNCLASSIFIED DRUG; VANDETANIB; VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB; ZD 7474;

ADVANCED CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; GASTROINTESTINAL TUMOR; GINGIVA BLEEDING; GYNECOLOGIC CANCER; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LUNG HEMORRHAGE; NEPHROTIC SYNDROME; NONHUMAN; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THROMBOEMBOLISM; TUMOR GROWTH; VAGINA BLEEDING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; LIGANDS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846933952     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.10.062     Document Type: Review

References (81)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 82 1 (1990) 4-6
2. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev., Cancer 3 6 (2003) 401-410
3. Risau W. Mechanisms of angiogenesis. Nature 386 6626 (1997) 671-674
4. Holash J., Wiegand S.J., and Yancopoulos G.D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18 38 (1999) 5356-5362
5. Hendrix M.J., Seftor E.A., Hess A.R., and Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev., Cancer 3 6 (2003) 411-421
6. Sood A.K., Seftor E.A., Fletcher M.S., Gardner L.M., Heidger P.M., Buller R.E., et al. Molecular determinants of ovarian cancer plasticity. Am. J. Pathol. 158 4 (2001) 1279-1288
7. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 4587 (1983) 983-985
8. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 4935 (1989) 1306-1309
9. Klagsbrun M., and D'Amore P.A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 7 3 (1996) 259-270
10. Thaker P.H., Han L.Y., Kamat A.A., Arevalo J.M., Takahashi R., Lu C., et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 12 8 (2006) 939-944
11. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 6 (2003) 669-676
12. Zhang L., Yang N., Garcia J.R., Mohamed A., Benencia F., Rubin S.C., et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am. J. Pathol. 161 6 (2002) 2295-2309
13. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20 21 (2002) 4368-4380
14. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 Suppl. 1 (2004) 2-10
15. Dvorak H.F., Brown L.F., Detmar M., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146 5 (1995) 1029-1039
16. Alon T., Hemo I., Itin A., Pe'er J., Stone J., and Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1 10 (1995) 1024-1028
17. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7 5 (2001) 575-583
18. Karkkainen M.J., Haiko P., Sainio K., Partanen J., Taipale J., Petrova T.V., et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5 1 (2004) 74-80
19. Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5 4 (1990) 519-524
20. Terman B.I., Carrion M.E., Kovacs E., Rasmussen B.A., Eddy R.L., and Shows T.B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6 9 (1991) 1677-1683
21. Fong G.H., Rossant J., Gertsenstein M., and Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376 6535 (1995) 66-70
22. Fong G.H., Zhang L., Bryce D.M., and Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 126 13 (1999) 3015-3025
23. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376 6535 (1995) 62-66
24. Takahashi T., Ueno H., and Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18 13 (1999) 2221-2230
25. Gerber H.P., Malik A.K., Solar G.P., Sherman D., Liang X.H., Meng G., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417 6892 (2002) 954-958
26. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 5 (2005) 1011-1027
27. Wedam S.B., Low J.A., Yang S.X., Chow C.K., Choyke P., Danforth D., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24 5 (2006) 769-777
28. Thaker P.H., Yazici S., Nilsson M.B., Yokoi K., Tsan R.Z., He J., et al. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin. Cancer Res. 11 13 (2005) 4923-4933
29. Kassim S.K., El-Salahy E.M., Fayed S.T., Helal S.A., Helal T., Azzam Eel D., et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin. Biochem. 37 5 (2004) 363-369
30. Paley P.J., Staskus K.A., Gebhard K., Mohanraj D., Twiggs L.B., Carson L.F., et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80 1 (1997) 98-106
31. Cooper B.C., Ritchie J.M., Broghammer C.L., Coffin J., Sorosky J.I., Buller R.E., et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res. 8 10 (2002) 3193-3197
32. Li L., Wang L., Zhang W., Tang B., Zhang J., Song H., et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 24 3b (2004) 1973-1979
33. Hefler L.A., Zeillinger R., Grimm C., Sood A.K., Cheng W.F., Gadducci A., et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol. Oncol. (2006)
34. Holland C.M., Day K., Evans A., and Smith S.K. Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br. J. Cancer 89 5 (2003) 891-898
35. Sanseverino F., Santopietro R., Torricelli M., D'Andrilli G., Russo G., Cevenini G., et al. pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade. Cancer Biol. Ther. 5 1 (2006) 84-88
36. Hirai M., Nakagawara A., Oosaki T., Hayashi Y., Hirono M., and Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol. Oncol. 80 2 (2001) 181-188
37. Loncaster J.A., Cooper R.A., Logue J.P., Davidson S.E., Hunter R.D., and West C.M. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br. J. Cancer 83 5 (2000) 620-625
38. Cheng W.F., Chen C.A., Lee C.N., Chen T.M., Hsieh F.J., and Hsieh C.Y. Vascular endothelial growth factor in cervical carcinoma. Obstet. Gynecol. 93 5 Pt 1 (1999) 761-765
39. Cheng W.F., Chen C.A., Lee C.N., Wei L.H., Hsieh F.J., and Hsieh C.Y. Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet. Gynecol. 96 5 Pt 1 (2000) 721-726
40. Tjalma W., Weyler J., Weyn B., Van Marck E., Van Daele A., Van Dam P., et al. The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 92 2 (2000) 251-257
41. Gombos Z., Xu X., Chu C.S., Zhang P.J., and Acs G. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin. Cancer Res. 11 23 (2005) 8364-8371
42. Lebrecht A., Ludwig E., Huber A., Klein M., Schneeberger C., Tempfer C., et al. Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer. Gynecol. Oncol. 85 1 (2002) 32-35
43. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 23 (2004) 2335-2342
44. Mesiano S., Ferrara N., and Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 153 4 (1998) 1249-1256
45. Hu L., Hofmann J., Zaloudek C., Ferrara N., Hamilton T., and Jaffe R.B. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am. J. Pathol. 161 5 (2002) 1917-1924
46. Burger R.A., Sill M., Monk B.J., Greer B., and Sorosky J. Phase II trial of bevacizumab in persistant or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol. vol. 23(16S) (2005) 5009
47. Cannistra S.A., Matulonis U., Penson R., Wenham R., Armstrong D., Burger R.A., et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 24(18S) (2006) 5006
48. Numnum T.M., Rocconi R.P., Whitworth J., and Barnes M.N. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol. Oncol. 102 3 (2006) 425-428
49. Monk B.J., Han E., Josephs-Cowan C.A., Pugmire G., and Burger R.A. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 102 2 (2006) 140-144
50. Bidus M.A., Webb J.C., Seidman J.D., Rose G.S., Boice C.R., and Elkas J.C. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol. Oncol. 102 1 (2006) 5-7
51. Teicher B.A., Holden S.A., Ara G., Sotomayor E.A., Huang Z.D., Chen Y.N., et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer 57 6 (1994) 920-925
52. Hu L., Hofmann J., Holash J., Yancopoulos G.D., Sood A.K., and Jaffe R.B. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin. Cancer Res. 11 19 Pt 1 (2005) 6966-6971
53. Landen Jr. C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65 15 (2005) 6910-6918
54. Halder J., Kamat A.A., Landen Jr. C.N., Han L.Y., Lutgendorf S.K., Lin Y.G., et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 12 16 (2006) 4916-4924
55. Han L.Y., Landen C.N., Trevino J.G., Halder J., Lin Y.G., Kamat A.A., et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res. 66 17 (2006) 8633-8639
56. Garcia A.A., Oza A.M., Hirte H., Fleming G., Tsao-Wei D., Roman L., et al. Interim report of a phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian and primary peritoneal cancer: a California Cancer Consortium Trial. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23 16S (2005) 5000
57. Cohn D.E., Valmadre S., Resnick K.E., Eaton L.A., Copeland L.J., and Fowler J.M. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol. Oncol. 102 2 (2006) 134-139
58. Wright J.D., Hagemann A., Rader J.S., Viviano D., Gibb R.K., Norris L., et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107 1 (2006) 83-89
59. Wright J.D., Viviano D., Powell M.A., Gibb R.K., Mutch D.G., Grigsby P.W., et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol. Oncol. (2006)
60. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A. 99 17 (2002) 11393-11398
61. Kim E.S., Serur A., Huang J., Manley C.A., McCrudden K.W., Frischer J.S., et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. U. S. A. 99 17 (2002) 11399-11404
62. Byrne A.T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J.I., et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9 15 (2003) 5721-5728
63. Dupont J., Bienvenu B., Aghajanian C., Pezzulli S., Sabbatini P., Vongphrachanh P., et al. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors. J. Clin. Oncol. 22 16 (2004) 3366-3374
64. Xu L., Yoneda J., Herrera C., Wood J., Killion J.J., and Fidler I.J. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J. Oncol. 16 3 (2000) 445-454
65. Rugo H.S., Herbst R.S., Liu G., Park J.W., Kies M.S., Steinfeldt H.M., et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 23 24 (2005) 5474-5483
66. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 1 (2003) 327-337
67. Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Chester R., Jackson J.A., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62 16 (2002) 4645-4655
68. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 19 (2004) 7099-7109
69. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24 16 (2006) 2505-2512
70. Siu L.L., Awada A., Takimoto C.H., Piccart M., Schwartz B., Giannaris T., et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin. Cancer Res. 12 1 (2006) 144-151
71. Zhang W., Ran S., Sambade M., Huang X., and Thorpe P.E. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 5 1-2 (2002) 35-44
72. Kuenen B.C., Rosen L., Smit E.F., Parson M.R., Levi M., Ruijter R., et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20 6 (2002) 1657-1667
73. F.D. Administration, Important Drug Warning-Bevacizumab. In; 2004.
74. Gordon M.S., and Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 69 Suppl. 3 (2005) 25-33
75. Hood J.D., Meininger C.J., Ziche M., and Granger H.J. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 274 3 Pt 2 (1998) H1054-H1058
76. Scappaticci F.A., Fehrenbacher L., Cartwright T., Hainsworth J.D., Heim W., Berlin J., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol. 91 3 (2005) 173-180
77. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 5706 (2005) 58-62
78. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Natl. Clin. Pract. Oncol. 3 1 (2006) 24-40
79. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21 1 (2003) 60-65
80. Willett C.G., Boucher Y., Tomaso diE., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10 2 (2004) 145-147
81. Bergers G., Song S., Meyer-Morse N., Bergsland E., and Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111 9 (2003) 1287-1295